High-level quinolone resistance in clinical isolates of Campylobacter jejuni.
During a recent clinical trial of ciprofloxacin in the therapy of acute diarrhea, two subjects infected with Campylobacter jejuni who received ciprofloxacin failed microbiologically and one also failed clinically. Although both pretreatment isolates were susceptible to ciprofloxacin, the posttreatment isolates were resistant to ciprofloxacin (MIC = 32 micrograms/ml) and to other quinolones. The posttreatment isolates remained susceptible to nonquinolone antimicrobials. DNA gyrase holoenzyme was isolated from one of the resistant posttreatment isolates and was 8- to 16-fold less sensitive to inhibition by ciprofloxacin than was the gyrase from the paired pretreatment susceptible isolate. Ciprofloxacin accumulation was diminished in the two resistant posttreatment isolates. These results show that mutation in C. jejuni can occur in vivo and is associated with clinically significant resistance to the newer quinolones.
Segreti
J
J
Rush Medical College, Chicago, IL 60612.
Gootz
T D
TD
Goodman
L J
LJ
Parkhurst
G W
GW
Quinn
J P
JP
Martin
B A
BA
Trenholme
G M
GM
D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001425:Bacterial Outer Membrane Proteins / Q000032:analysis; D002169:Campylobacter Infections / Q000188:drug therapy / Q000382:microbiology*; D016123:Campylobacter jejuni / Q000737:chemistry / Q000187:drug effects* / Q000235:genetics; D002939:Ciprofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D009154:Mutation; D012692:Serial Passage; D059005:Topoisomerase II Inhibitors
D000890:Anti-Infective Agents; D001425:Bacterial Outer Membrane Proteins; D059005:Topoisomerase II Inhibitors; D002939:Ciprofloxacin